Skin · Melanocortin agonist · Investigational
Melanotan-2: the melanocortin agonist explained.
Melanotan-2 (MT-2) is a synthetic non-selective melanocortin receptor agonist developed in the 1980s at the University of Arizona. It binds MC1R (skin pigmentation), MC3R / MC4R (libido and appetite), and MC5R — producing dose-dependent skin darkening, libido changes, and appetite suppression. The closely related approved drug PT-141 (bremelanotide) is the FDA-cleared MC4R-selective successor.
What Melanotan II is
Melanotan-2 is a synthetic cyclic heptapeptide analog of alpha-MSH (alpha-melanocyte-stimulating hormone). It was originally developed at the University of Arizona in the 1980s as a candidate sunless tanning agent for prevention of melanoma in fair-skinned populations.
Commercial development was discontinued in favor of a more selective derivative, bremelanotide (PT-141), which is FDA-approved for HSDD. MT-2 itself has never been approved by the FDA or EMA.
It remains widely used in unregulated channels for cosmetic tanning. kindr's position is honest education: MT-2 is investigational; patients seeking the libido application should look at the FDA-approved alternative (PT-141); patients seeking tanning should be informed of the real risks.
How it works
MT-2 activates MC1R on melanocytes in the skin, upregulating tyrosinase and increasing eumelanin synthesis — producing real, dose-dependent skin darkening.
It also activates MC3R and MC4R in the CNS, producing increased sexual arousal (the same mechanism PT-141 leverages selectively), reduced food intake, and occasionally nausea.
Non-selective MC5R activity may contribute to side effects (yawning, sebaceous gland stimulation, flushing).
What patients use it for
Pigmentation increase
Real, measurable melanin upregulation — the original therapeutic intent. Used in research for vitiligo and erythropoietic protoporphyria.
Libido and arousal effects
Produces meaningful libido and arousal effects via central MC4R — the same mechanism leveraged more selectively by FDA-approved PT-141 (bremelanotide).
Appetite suppression
Central MC4R activation reduces food intake — though typically not a primary therapeutic use.
Evidence summary
Dorr RT et al. (Life Sci, 1996) — original Arizona program characterizing MT-2's pigmentation and arousal effects in humans.
Hadley ME (Ann N Y Acad Sci, 2005) reviewed melanocortin agonist development history.
Cardinal et al. multiple case reports of MT-2-associated melanocytic-nevus changes and rare reports of melanoma after unregulated use.
MT-2 has never completed Phase III trials and is not FDA-approved. The closest approved analog is bremelanotide (PT-141), MC4R-selective, FDA-approved for HSDD in 2019.
Dosing and clinical context
General clinical context only. Kindr Health physicians determine the appropriate dose and protocol for each patient based on history and labs. This is not a prescription or dosing recommendation.
MT-2 is generally not prescribed by responsible clinical practices in the U.S. for cosmetic tanning use due to the unfavorable risk-benefit profile.
Patients interested in the libido application should consider FDA-approved PT-141 (bremelanotide), which provides the desired effect with a much cleaner regulatory and safety profile.
Patients with legitimate medical pigmentation disorders (vitiligo, EPP) should work with a dermatologist — not unregulated channels.
Safety and contraindications
Significant concerns include darkening and proliferation of existing melanocytic nevi (moles), risk of new atypical nevi, and case reports of melanoma associated with unregulated use.
Common side effects: nausea (often pronounced), flushing, spontaneous penile erections (priapism risk), darkening of moles, freckles, and lips.
Unregulated injectable MT-2 has documented contamination and dosing-error risks — a major reason kindr does not prescribe it for tanning use.
Contraindications: history of melanoma, dysplastic nevus syndrome, pregnancy/lactation, cardiovascular disease, uncontrolled hypertension.
Who it's typically considered for
- Honest framing: kindr does not recommend MT-2 for cosmetic tanning use. The dermatologic and oncologic risks outweigh the cosmetic benefit.
- Patients interested in libido/arousal effects: see PT-141 (bremelanotide), the FDA-approved selective MC4R analog.
- Patients with diagnosed pigmentation disorders should work with board-certified dermatology — not peptide channels.
Frequently asked questions
Will kindr prescribe Melanotan-2 for tanning?
No. Our clinical position is that the dermatologic and melanoma-associated risks of MT-2 for cosmetic tanning outweigh the benefit. We prefer to redirect patients to FDA-approved alternatives where they exist.
MT-2 vs PT-141?
PT-141 (bremelanotide) is MC4R-selective and FDA-approved for HSDD in premenopausal women. It delivers the libido / arousal application of MT-2 without the non-selective pigmentation and mole effects, and without the regulatory uncertainty.
Does MT-2 actually tan you?
Yes — it produces real, dose-dependent skin darkening. But it also darkens existing moles, can produce new atypical nevi, and has been associated in case reports with melanoma.
Is MT-2 legal?
Not FDA-approved. Sold widely in unregulated channels, often with significant quality-control issues. We do not source from these channels.
I already use MT-2 — what should I do?
Stop, see a dermatologist for a full skin and nevus check, and consider transitioning to PT-141 if libido was the goal. Schedule annual dermatology surveillance going forward.
What about Melanotan-1?
Afamelanotide (Melanotan-1, brand Scenesse) is FDA-approved specifically for erythropoietic protoporphyria — a rare genetic condition. It is not a cosmetic tanning option.
Sources
- Dorr RT et al. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide. Life Sci (1996). — pubmed.ncbi.nlm.nih.gov/8847885
- Cardones AR, Grichnik JM. α-Melanocyte-stimulating hormone-induced eruptive nevi. Arch Dermatol (2009). — pubmed.ncbi.nlm.nih.gov/19380658
- FDA Approval Label — Vyleesi (bremelanotide), the MC4R-selective successor. — www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
Considering Melanotan II?
A Kindr Health physician reviews every longevity intake — peptides are prescribed only when medically indicated based on your history and labs. There is no charge for the initial review.
Start your longevity intake →Related peptides
Medically reviewed by Dr. Ana Lisa Carr, MD, MBA
Board-Certified Family Medicine Physician · Lead Provider / Medical Reviewer
NPI 1689841744 · Last reviewed: May 10, 2026
Last reviewed May 10, 2026. Compounded medications are prepared by FDA-registered 503A pharmacies and are not FDA-approved drug products. Prescriptions require a clinical evaluation; a Kindr Health physician determines eligibility. Not for use in pregnancy. This page provides educational information and is not medical advice.